<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03915132</url>
  </required_header>
  <id_info>
    <org_study_id>NCC1937</org_study_id>
    <nct_id>NCT03915132</nct_id>
  </id_info>
  <brief_title>Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma</brief_title>
  <official_title>Phase II Trial of Nimotuzumab Combined With Volumetric Modulated Arc Therapy in Elderly Patients With Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and toxicity of Nimotuzumab combined with VMAT in the treatment of
      elderly patients with nasopharyngeal carcinoma (&gt; 70 years old), and to provide high-level
      clinical evidence for the optimal treatment of elderly patients with nasopharyngeal
      carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of elderly patients with nasopharyngeal carcinoma is increasing with a rapidly
      ageing population. However, the prognosis is worse than that of young patients. Some patients
      can benefit from intensive treatment such as concurrent chemoradiotherapy, but are always
      with obvious toxicity. With the advancement of radiotherapy technology and the emergence of
      molecular targeted drugs, radiotherapy combined with Nimotuzumab has shown good therapeutic
      efficacy and tolerance. The investigators plan to testify VMAT combined with Nimotuzumab in
      elderly patients with nasopharyngeal carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>4 months</time_frame>
    <description>Complete remission rate will be measured by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute treatment toxicity</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>Acute toxicity will be measured by CTCAE4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment</measure>
    <time_frame>2 years</time_frame>
    <description>EORTC,QLQ-C30 Version 3.0 are used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>regional control rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late treatment toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>late toxicity will be measured by CTCAE4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>VMAT plus Nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Nimotuzumab weekly during radiotherapy .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>Nimotuzumab 200mg/m2 IV on d1 of a week before radiotherapy , and 100mg/m2 IV on d1 weekly for 7 cycles</description>
    <arm_group_label>VMAT plus Nimotuzumab</arm_group_label>
    <other_name>Taixinsheng</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>VMAT</intervention_name>
    <description>Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume.</description>
    <arm_group_label>VMAT plus Nimotuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathology confirmed squamous cell carcinoma of nasopharynx; Aged ≥ 70 years old; Stage
             III-IVB diseases according to 8th AJCC Staging; Treatment for the first time; ECOG
             scores ≤ 1; Normal hepatic, renal and bone-marrow function; ACE-27 scores ≤2; Life
             expectancy≥12 weeks; Can understand and sign the consent.

        Exclusion Criteria:

          -  Past malignancies history (except for non-melanoma skin cancer or cervical carcinoma
             in situ or cured prostate cancer of early stage); Allergic to Nimotuzumab; Severe
             comorbidities including cardiovascular, cerebral vascular, mental and uncontrolled
             diabetes disease; Chemotherapy, surgery or other molecule-target treatment; Severe
             malnutrition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Zhang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ye zhang, MD</last_name>
    <phone>8610-87787625</phone>
    <email>drzye1983@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junlin Yi, M.D</last_name>
    <phone>861087788504</phone>
    <email>junlinyi@sohu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijin</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Zhang</last_name>
      <phone>8610-87787625</phone>
      <phone_ext>13717635880</phone_ext>
      <email>drzye1983@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cao C, Hu Q, Chen X. Intensity-modulated radiotherapy for elderly patients with nasopharyngeal carcinoma. Head Neck. 2018 Mar;40(3):590-595. doi: 10.1002/hed.25016. Epub 2017 Nov 20.</citation>
    <PMID>29155480</PMID>
  </reference>
  <reference>
    <citation>Liu H, Chen QY, Guo L, Tang LQ, Mo HY, Zhong ZL, Huang PY, Luo DH, Sun R, Guo X, Cao KJ, Hong MH, Mai HQ. Feasibility and efficacy of chemoradiotherapy for elderly patients with locoregionally advanced nasopharyngeal carcinoma: results from a matched cohort analysis. Radiat Oncol. 2013 Mar 22;8:70. doi: 10.1186/1748-717X-8-70.</citation>
    <PMID>23521779</PMID>
  </reference>
  <results_reference>
    <citation>Zhang Y, Yi JL, Huang XD, Xu GZ, Xiao JP, Li SY, Luo JW, Zhang SP, Wang K, Qu Y, Gao L. Inherently poor survival of elderly patients with nasopharyngeal carcinoma. Head Neck. 2015 Jun;37(6):771-6. doi: 10.1002/hed.23497. Epub 2015 Feb 11.</citation>
    <PMID>24115004</PMID>
  </results_reference>
  <results_reference>
    <citation>Jin YN, Zhang WJ, Cai XY, Li MS, Lawrence WR, Wang SY, Mai DM, Du YY, Luo DH, Mo HY. The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era. Cancer Res Treat. 2019 Jan;51(1):34-42. doi: 10.4143/crt.2017.551. Epub 2018 Feb 6.</citation>
    <PMID>29409313</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 31, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Li Gao</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>VMAT</keyword>
  <keyword>Nimotuzumab</keyword>
  <keyword>Elderly Patients</keyword>
  <keyword>efficacy</keyword>
  <keyword>toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

